Contineum Therapeutics CSO Daniel S. Lorrain disposes of USD 16,640 in common shares - CTNM News | RalliesContineum Therapeutics CSO Daniel S. Lorrain disposes of USD 16,640 in common shares
C
CTNM• Insider share sale and option exercises
- Contineum Therapeutics Chief Scientific Officer Daniel S. Lorrain sold 1,040 Class A common shares at USD 16 on July 8-9.
- The sales followed option exercises for 1,040 shares at USD 1.01, leaving direct ownership at 135,202 shares.
- He reported 33,257 stock options remaining, exercisable at USD 1.01, expiring Feb. 24, 2030.
•
